Aldeyra Therapeutics (NASDAQ:ALDX) CEO Purchases $417,500.00 in Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) CEO Todd Brady purchased 250,000 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average price of $1.67 per share, with a total value of $417,500.00. Following the purchase, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at approximately $2,874,567.66. The trade was a 16.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aldeyra Therapeutics Trading Down 7.4%

Shares of Aldeyra Therapeutics stock traded down $0.13 on Friday, reaching $1.63. 946,125 shares of the stock were exchanged, compared to its average volume of 2,162,364. The firm has a market capitalization of $98.32 million, a PE ratio of -3.54 and a beta of 1.19. Aldeyra Therapeutics, Inc. has a 1-year low of $1.07 and a 1-year high of $6.18. The business has a fifty day moving average price of $1.68 and a two-hundred day moving average price of $3.69.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. Research analysts expect that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current year.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALDX. Renaissance Technologies LLC raised its stake in Aldeyra Therapeutics by 146.6% during the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock worth $1,459,000 after purchasing an additional 513,187 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Aldeyra Therapeutics by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock valued at $1,055,000 after buying an additional 11,912 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Aldeyra Therapeutics by 18.1% during the 1st quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock worth $231,000 after buying an additional 20,980 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth $33,000. Finally, Abel Hall LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth $26,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

ALDX has been the topic of a number of recent research reports. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, March 18th. Finally, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.